文献速递眼底病与葡萄膜炎

共享表位拮抗环肽Clarstatin对小鼠实验性自身免疫性葡萄膜炎的抗炎作用

Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

研究探讨Clarstatin(一种HLA共享表位-钙网蛋白相互作用的环肽拮抗剂)在实验性自身免疫性葡萄膜炎(EAU)小鼠模型中的治疗作用。小鼠腹腔注射Clarstatin并与皮质类固醇比较,结果显示Clarstatin显著减轻C57BL/6J轻度及B10.RIII重度EAU模型的严重程度,临床评分、组织学评分及CD45+细胞数呈30%至80%的剂量和时间依赖性下降(P<0.05),效果与皮质类固醇相当;眼内IL-6和MCP-1分别降低41%和59%。

要点

  • Clarstatin显著改善C57BL/6J轻度及B10.RIII重度EAU模型的严重程度。
  • 临床评分、组织学评分及视网膜和脾脏CD45+细胞数呈30%至80%的剂量和时间依赖性下降,效果与皮质类固醇相当。
  • Clarstatin使眼内IL-6降低41%(P<0.05)、MCP-1降低59%(P<0.01)。

核心结论

  • 全身给予Clarstatin显著改善轻度和重度EAU,其潜在抗炎治疗作用代表眼部炎症的一种新治疗模式。
  • Clarstatin也可能成为钙网蛋白在其发病机制中起作用的系统性自身免疫病的相关治疗方式。

研究设计与样本

  • 小鼠腹腔注射Clarstatin,并与皮质类固醇的效果进行比较。
  • 通过临床和组织学评估EAU,用免疫荧光和流式细胞术(FACS)检测CD45+造血细胞的眼部浸润和脾细胞CD4+表达,用ELISA测定眼内促炎细胞因子水平。

主要发现

  • Clarstatin显著减轻C57BL/6J轻度及B10.RIII重度EAU小鼠模型的严重程度。
  • 临床评分、组织学评分及视网膜和脾脏CD45+细胞数呈30%至80%的剂量和时间依赖性下降(临床评分P<0.05,组织学评分P<0.05,视网膜CD45+细胞P<0.05,脾脏CD45+细胞P<0.001),效果与皮质类固醇相当。
  • Clarstatin使眼内IL-6降低41%(P<0.05)、MCP-1降低59%(P<0.01)。

临床怎么用

  • 原文结论认为Clarstatin的潜在抗炎治疗作用代表眼部炎症的一种新治疗模式。
  • 原文结论认为Clarstatin也可能成为钙网蛋白在其发病机制中起作用的系统性自身免疫病的相关治疗方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Polymorphism and mutations of human leukocyte antigens (HLAs) and calreticulin are risk factors for uveitis. Here, we sought to determine the therapeutic effects of Clarstatin, a cyclic peptide antagonist of the HLA shared-epitope-calreticulin interaction, in experimental autoimmune uveitis (EAU) models. METHODS: Mice were injected with Clarstatin intraperitoneally and its effect was compared to that of corticosteroid. EAU was evaluated clinically and histologically. Ocular infiltration of CD45+ hematopoietic cells and splenocyte CD4+ expression were determined using immunofluorescence and flow cytometry (fluorescence-activated cell sorting [FACS]). ELISA was used to measure the ocular level of the proinflammatory cytokines. RESULTS: Clarstatin significantly ameliorated the severity of EAU in the C57BL/6J mild and the B10.RIII severe mice models. There was a significant dose and time-dependent decrease, in the range of 30% to 80%, in the clinical score (P < 0.05), histological score (P < 0.05), and number of retinal and spleen CD45+ cells (P < 0.05 and P < 0.001, respectively), a comparable effect to corticosteroid. Clarstatin reduced the intraocular levels of interleukin 6 (IL-6; P < 0.05) and monocyte chemoattractant protein-1 (MCP-1; P < 0.01) by 41% and 59%, respectively. CONCLUSIONS: Systemic delivery of Clarstatin significantly improved mild and severe EAU. Its potential anti-inflammatory therapeutic effects represent a novel mode of treatment in ocular inflammation. It may also be a relevant treatment modality in systemic autoimmune conditions in which calreticulin plays a role in their pathogenesis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Merzbach S, Schumacher-Klinger A, Klazas M, et al. Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice. Invest Ophthalmol Vis Sci. 2025. PMID: 39775697. doi:10.1167/iovs.66.1.13

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。